Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes by more than half in patients with a rare endocrine disease.
- Home |
- Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
- August 17, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
